近年来对抗乙肝病毒的药物研究,取得了相当多的进展,目前干扰素的治疗作用已基本上取得共识。抗乙肝病毒的新药开发,如雨后春笋,现在一些抗HBV的口服药物已被用于临床的Ⅱ期和Ⅲ期试验,包括象拉米夫定、法昔洛韦、洛布卡韦和阿地福韦等核苷类药物。这些新的核苷酸或核苷酸类似物在抗乙肝病毒方面与α-干扰素相比,具有更大的抗病毒潜能。但这些药物的治疗效果距理想的程度还 In recent years, the research on the drug against hepatitis B virus has made considerable progress. At present, the therapeutic effect of interferon has basically reached a consensus. New anti-hepatitis B drug development, springing up, and now some anti-HBV oral drugs have been used in clinical phase Ⅱ and Ⅲ trials, including such as lamivudine, famciclovir, lo bukavir and adefovir Wei and other nucleoside drugs. These new nucleotides or nucleotide analogs have a greater antiviral potential in anti-hepatitis B virus activity than interferon-alpha. However, the therapeutic effect of these drugs from the ideal level still